logo
logo
Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc.

NASDAQ•ACRS
CEO: Dr. Neal S. Walker D.O., M.D.
セクター: Healthcare
業種: Medical - Diagnostics & Research
上場日: 2015-10-06
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
連絡先情報
701 Lee Road, Suite 103, Wayne, PA, 19087, United States
484-324-7933
www.aclaristx.com
時価総額
$353.21M
PER (TTM)
-2.8
20.1
配当利回り
--
52週高値
$4.89
52週安値
$1.05
52週レンジ
58%
順位45Top 56.8%
3.6
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 3.6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$3.30M-24.09%
直近4四半期の推移

EPS

-$0.12+9.09%
直近4四半期の推移

フリーCF

-$10.96M-149.79%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

R&D Investment Surge Nine month R&D expenses reached $36.06M, increasing $11.50M over prior year period, supporting pipeline.
Pipeline Progress Updates ATI-2138 Phase 2a trial showed 77% mean EASI improvement; Bosakitug Phase 2 trial initiated June 2025.
Stable Cash Position Cash, cash equivalents totaled $25.26M as of September 30, 2025; sufficient for over 12 months operations.
Net Loss Per Share Improved Nine month net loss per share improved in magnitude to $(0.37) compared to $(0.50) in 2024.

リスク要因

Operating Loss Widened Nine month net loss widened to $(45.13)M from $(35.51)M, demanding substantial future capital infusion.
Total Revenue Decline Total revenue declined $2.98M for nine months, driven by lower contract research hours billed year-to-date.
Contingent Liability Growth Contingent consideration liability grew $1.90M to $10.60M, highly dependent on uncertain future milestone achievement.
Increased R&D Spending Research and development costs increased $11.50M, accelerating cash burn rate for ongoing clinical programs.

見通し

Bosakitug Data Expected Expect top-line data for Bosakitug Phase 2 trial in H2 2026; exploring respiratory indication partnerships.
Next-Gen ITK Filing Progressing next-generation ITK selective inhibitors toward IND application filing submission in the second half of 2026.
ATI-2138 Indication Expansion Planning Phase 2 trial initiation for ATI-2138 in additional indications during the first half of 2026.

同業比較

売上高 (TTM)

Owens & Minor, Inc.OMI
$6.71B
+44.5%
NeoGenomics, Inc.NEO
$727.33M
+10.1%
Atlantic International Corp.ATLN
$445.38M
+3.8%

粗利益率 (最新四半期)

Editas Medicine, Inc.EDIT
100.0%
+2621.3pp
Orchestra BioMed Holdings, Inc.OBIO
94.3%
+1.2pp
Invivyd, Inc.IVVD
91.7%
+0.4pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
ALLO$485.42M-2.3-57.8%19.4%
ACRS$353.21M-2.8-102.8%1.3%
SENS$308.48M-5.2-135.2%29.4%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-29.0%
成長鈍化
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年2月26日
|
EPS:-$0.15
|
売上高:-
財務レポート
財務データ
ニュース
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月6日|
    売上高: $3.30M-24.1%
    |
    EPS: $-0.12+9.1%
    予想を上回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月7日|
    売上高: $1.78M-35.8%
    |
    EPS: $-0.13-13.3%
    予想を上回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月8日|
    売上高: $1.46M-39.3%
    |
    EPS: $-0.12-50.0%
    予想通り

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月27日|
    売上高: $18.72M-40.1%
    |
    EPS: $-1.71-34.6%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月6日|
    売上高: $4.35M-53.2%
    |
    EPS: $-0.11-73.2%
    予想を下回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月7日|
    売上高: $2.77M+48.0%
    |
    EPS: $-0.15-64.3%
    予想を上回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月7日|
    売上高: $2.40M-5.1%
    |
    EPS: $-0.24-38.5%
    予想を上回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月27日|
    売上高: $31.25M+5.0%
    |
    EPS: $-1.27+4.5%
    予想を下回る